The spectrum of statin therapy in cancer patients: Is there a need for further investigation? topical collection on statin drugs

Current Atherosclerosis Reports

Volumn 16, Issue 1, 2014, Pages

  Gonyeau, Michael J ^a  

^a NORTHEASTERN UNIVERSITY   (United States)

Author keywords

3 Hydroxy 3 methylglutaryl coenzyme a reductase inhibitors; Breast cancer; Cancer; Clinical trials; Colorectal cancer; Lung cancer; Neoplasm; Pleiotropic effects; Prostate cancer; Statins

Indexed keywords

ATORVASTATIN; CHOLESTEROL; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; HYPOCHOLESTEROLEMIC AGENT; LOW DENSITY LIPOPROTEIN CHOLESTEROL; PRAVASTATIN; ROSUVASTATIN; SIMVASTATIN;

ARTICLE; BLADDER CANCER; BREAST CANCER; CANCER INCIDENCE; CANCER INHIBITION; CANCER MORTALITY; CANCER PATIENT; CANCER RISK; CARDIOVASCULAR DISEASE; CHOLESTEROL BLOOD LEVEL; COLORECTAL CANCER; DISEASE ASSOCIATION; DRUG MECHANISM; DRUG USE; ENDOMETRIUM CANCER; ESOPHAGEAL ADENOCARCINOMA; HUMAN; KIDNEY CANCER; LUNG CANCER; MELANOMA; NEOPLASM; NONHODGKIN LYMPHOMA; PANCREAS CANCER; PROSTATE CANCER; RISK FACTOR; RISK REDUCTION; SKIN CANCER; ANIMAL; CLINICAL TRIAL (TOPIC); INCIDENCE; MORTALITY; REVIEW; RISK; TREATMENT OUTCOME;

ANIMALS; CLINICAL TRIALS AS TOPIC; HUMANS; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; INCIDENCE; NEOPLASMS; RISK; TREATMENT OUTCOME;

EID: 84888814077     PISSN: 15233804     EISSN: 15346242     Source Type: Journal    
DOI: 10.1007/s11883-013-0383-z     Document Type: Article

References (38)

1. Gonyeau MJ, Yuen DW. A clinical review of statins and cancer: helpful or harmful? Pharmacotherapy. 2010;30(2):177-94.
2. McLaughlin-Drubin ME, Munger K. Viruses associated with human cancer. Biochim Biophys Acta. 2008;1782:127-50.
3. Han R. Plasma lipoproteins are important components of the immune system. Microbiol Immunol. 2010;54:246-53.
4. Smith PF, Grossman SJ, Gerson RJ, et al. Studies on the mechanism of simvastatin-induced thyroid hypertrophy and follicular cell adenoma in the rat. Toxicol Pathol. 1991;19:197-205.
5. Chen CL, Huang SS, Huang JS. Cholesterol modulates cellular TGF-β responsiveness by altering TGF-β binding to TGF-β receptors. J Cell Physiol. 2008;215:223-33.
6. Lamprecht J, Wojcik C, Jakobisiak M, Stoehr M, Schrorter D, Paweletz N. Lovastatin induces mitotic abnormalities in various cell lines. Cell Biol Int. 1999;23:51-60.
7. Weitz-Schmidt G, Welzenbach K, Brinkmann V, et al. Statins selectively inhibit leukocyte function antigen-1 by binding to a novel regulatory integrin site. Nat Med. 2001;7:687-92.
8. Watanabe M, Koike H, Ishiba T, Okada T, Seo S, Hirai K. Synthesis and biological activity of methane sulfonyl pyrrole- substituted 3,4-dihydroxy-6-heptanoates: a novel series of HMG-CoA reductase inhibitors. Bioorg Med Chem. 1997;5:437-44.
9. Hindler K, Cleeland CS, Rivera E, Collard CD. The role of statins in cancer therapy. Oncologist. 2006;11:306-15.
10. Wejde J, Hjertman M, Carlberg M, et al. Dolichol-like lipids with stimulatory effect on DNA synthesis: substrates for protein dolichylation? J Cell Biochem. 1998;71:502-14.
11. Adjei AA. Blocking oncogenic Ras signaling for cancer therapy. J Natl Cancer Inst. 2001;93:1062-74.
12. Okumadu C, Dutta A. p21-dependent inhibition of colon cancer cell growth by mevastatin is independent of inhibition of G1 cyclin-dependent kinases. J Biol Chem. 2003;278:43586-94.
13. Dulak J, Jozkowicz A. Anti-angiogenic and anti-inflammatory effects of statins: relevance to anti-cancer therapy. Curr Cancer Drug Targets. 2005;5:579-94.
14. Frick M, Dulak J, Cisowski J, et al. Statins differentially regulate vascular endothelial growth factor in endothelial and vascular smooth muscle cells. Atherosclerosis. 2003;170:229-36.
15. De Four KJS, Paleolog E, Sandison A, Cohen P, Dawson PM. Does statin treatment alter VEGF and HIF expression in human colorectal cancer? An immunohistochemical (IHC) approach. Poster 10328 presented at: The complete surgeon. Association of Surgeons of Great Britain and Ireland annual scientific meeting 2006. 2006 May 3-5; Edinburgh.
16. Kureishi Y, Luo Z, Shiojima I, et al. The HMG-CoA reductase inhibitor simvastatin activates the protein kinase Akt and promotes angiogenesis in normocholesterolemic animals. Nat Med. 2000;6:1004-10.
17. Brouet A, Sonveaux P, Dessy C, et al. Hsp90 and caveolin are key targets for the proangiogenic nitric oxide-mediated effects of statins. Circ Res. 2001;89:866-73.
18. Weis M, Heeschen C, Glassford AJ, Cooke JP. Statins have biphasic effects on angiogenesis. Circulation. 2002;105:739-45.
19. Schaefer CA, Kuhlmann CR, Gast C, et al. Statins prevent oxidized low-density lipoprotein- and lysophosphatidylcholine-induced proliferation of human endothelial cells. Vasc Pharmacol. 2004;41:67-73.
20. Wang IK, Lin-Shiau SY, Lin JK. Suppression of invasion and MMP-9 expression in NIH 3T3 and v-H-Ras 3T3 fibroblasts by lovastatin through inhibition of ras isoprenylation. Oncology. 2000;59:245-54.
21. Kusama T, Mukai M, Iwasaki T, et al. Inhibition of epidermal growth factor-induced RhoA translocation and invasion of human pancreatic cancer cells by 3-hydroxy-3-methylglutaryl-coenzyme A reductase inhibitors. Cancer Res. 2001;61:4885-91.
22. Hanahan D, Weinberg RA. The hallmarks of cancer. Cell. 2000;100:57-70.
23. Mo H, Elson CE. Studies of the isoprenoid-mediated inhibition of mevalonate synthesis applied to cancer chemotherapy and chemoprevention. Exp Biol Med. 2004;229:567-85.
24. Cafforio P, Dammacco F, Gernone A, Silvestris F. Statins activate the mitochondrial pathway of apoptosis in human lymphoblasts and myeloma cells. Carcinogenesis. 2005;26:883-91.
25. Ravnskov U, McCully KS, Rosch PJ. The statin-low cholesterol-cancer conundrum. QJM. 2012;105(4):383-8.
26. Benn M, Tybjærg-Hansen A, Stender S, et al. Low-density lipoprotein cholesterol and the risk of cancer: a mendelian randomization study. J Natl Cancer Inst. 2011;103(6):508-19.
27. Emberson JR, Kearney PM, Blackwell L, et al. Lack of effect of lowering LDL cholesterol on cancer: meta-analysis of individual data from 175,000 people in 27 randomised trials of statin therapy. PLoS One. 2012;7(1):e29849. This meta-analysis of 22 randomized control trials of statins with a mean duration of almost five years revealed that lipid lowering from statins did not affect diagnosis of new cancer or cancer related mortality at any of the 23 individual specific cancer types assessed. The study also showed that patients with low baseline LDL, a sub group in which statin induced cancer is worrisome, found no increase in cancer risk versus the rest of the study population.
28. Jacobs EJ, Newton CC, Thun MJ, et al. Long-term use of cholesterol-lowering drugs and cancer incidence in a large United States cohort. Cancer Res. 2011;71:1763-71. This article describes a sub-group analysis of 133,255 participants (60,059 men and 73,196 women) in the Cancer Prevention Study II Nutrition Cohort from 1997 to 2007. Results revealed that statin use for five or more years was not associated with overall cancer incidence (RR = 0.97, 95% CI = 0.92-1.03), or incidence of a number of site specific cancers (prostate, breast, colorectal, lung, bladder, renal cell, or pancreatic cancer). Statins were actually associated with a lower risk of melanoma (RR = 0.79, 95% CI = 0.66-0.96), endometrial cancer (RR = 0.65, 95% CI = 0.45-0.94), and non-Hodgkin lymphoma (NHL; RR = 0.74, 95% CI = 0.62-0.89). The authors of this study postulate that statin use of five years or more is unlikely to substantially affect overall cancer risk. While this is an observational trial and cannot prove causality, it is a large patient population and would seem indicative of common statin use in the U.S.
29. Calle EE, Rodriguez C, Jacobs EJ, Almon ML, Chao A, McCullough ML, et al. The American Cancer Society Cancer Prevention Study II Nutrition Cohort - rationale, study design and baseline characteristics. Cancer. 2002;94:2490-501.
30. Ahern TP, Pedersen L, Tarp M, et al. Statin prescriptions and breast cancer recurrence risk: a Danish nationwide prospective cohort study. J Natl Cancer Inst. 2011;103(19):1461-8.
31. Nielsen SF, Nordestgaard BG, Bojesen SE. Statin use and reduced cancer-related mortality. N Engl J Med. 2012;367(19):1792-802. Very large population based observational trial of the entire Danish population with a diagnosis of cancer between 1995 and 2007. Prior to cancer diagnosis, statin users (18,721) were compared to non-users (277,204), and a multivariable- adjusted hazard ratio was found to be 0.85 (95% CI 0.83 to 0.87) for death from any cause and 0.85 (95% CI, 0.82 to 0.87) for death from cancer. Despite its observational nature and lack of ability to prove causality, this study is significant for its large study population and significant potential protective effects of statins on cancer mortality as well as death from any cause. This trial highlights potential for statins that warrant further investigation.
32. Friedman GD, Flick ED, Udaltsova N, Chan J, Quesenberry CP Jr, Habel LA. Screening statins for possible carcinogenic risk: up to 9 years of follow-up of 361,859 recipients. Pharmacoepidemiol Drug Saf. 2008;1727-36.
33. Crivelli JJ, Xylinas E, Kluth LA, et al. Effect of statin use on outcomes of non-muscle-invasive bladder cancer. BJU Int. 2013;112(2):E4-E12.
34. Peng X, Li W, Yuan L, Mehta RG, et al. Inhibition of proliferation and induction of autophagy by atorvastatin in PC3 prostate cancer cells correlate with downregulation of Bcl2 and upregulation of miR-182 and p21. PLoS One. 2013;8(8):e70442.
35. Bansal D, Undela K, D'Cruz S, et al. Statin use and risk of prostate cancer: a meta-analysis of observational studies. PLoS One. 2012;7(10):e46691.
36. Beales ILP, Hensley A, Loke Y. Reduced esophageal cancer incidence in statin users, particularly with cyclo-oxygenase inhibition. World J Gastrointest Pharmacol Ther. 2013;4(3):69.
37. Roy M, Kung HJ, Ghosh PM. Statins and prostate cancer: role of cholesterol inhibition vs. prevention of small GTP-binding proteins. Am J Cancer Res. 2011;1(4):542-61.
38. Boudreau DM, Yu O, Johnson J. Statin use and cancer risk: a comprehensive review. Expert Opin Drug Saf. 2010;9(4):603-21.